Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, Stockholm, Sweden.
Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Clin Cancer Res. 2019 Jun 15;25(12):3702-3717. doi: 10.1158/1078-0432.CCR-18-1294. Epub 2019 Mar 8.
Fibroblasts expressing the orphan chemokine CXCL14 have been previously shown to associate with poor breast cancer prognosis and promote cancer growth. This study explores the mechanism underlying the poor survival associations of stromal CXCL14.
Tumor cell epithelial-to-mesenchymal transition (EMT), invasion, and metastasis were studied in and models together with fibroblasts overexpressing CXCL14. An approach for CXCL14 receptor identification included loss-of-function studies followed by molecular and functional endpoints. The clinical relevance was further explored in publicly available gene expression datasets.
CXCL14 fibroblasts stimulated breast cancer EMT, migration, and invasion in breast cancer cells and in a xenograft model. Furthermore, tumor cells primed by CXCL14 fibroblasts displayed enhanced lung colonization after tail-vein injection. By loss-of function experiments, the atypical G-protein-coupled receptor ACKR2 was identified to mediate CXCL14-stimulated responses. Downregulation of ACKR2, or CXCL14-induced NOS1, attenuated the pro-EMT and migratory capacity. CXCL14/ACKR2 expression correlated with EMT and survival in gene expression datasets.
Collectively, the findings imply an autocrine fibroblast CXCL14/ACKR2 pathway as a clinically relevant stimulator of EMT, tumor cell invasion, and metastasis. The study also identifies ACKR2 as a novel mediator for CXCL14 function and thereby defines a pathway with drug target potential..
先前已经证明表达孤儿趋化因子 CXCL14 的成纤维细胞与不良乳腺癌预后相关,并促进癌症生长。本研究探讨了基质 CXCL14 与不良生存相关的潜在机制。
研究了和模型中肿瘤细胞上皮-间充质转化 (EMT)、侵袭和转移情况,以及过表达 CXCL14 的成纤维细胞。CXCL14 受体鉴定的方法包括功能丧失研究,然后是分子和功能终点。还在公开的基因表达数据集进一步探讨了临床相关性。
CXCL14 成纤维细胞刺激乳腺癌 EMT、迁移和侵袭在乳腺癌细胞中和异种移植模型中。此外,经 CXCL14 成纤维细胞预先刺激的肿瘤细胞在尾静脉注射后显示出增强的肺定植能力。通过功能丧失实验,鉴定出非典型 G 蛋白偶联受体 ACKR2 介导 CXCL14 刺激的反应。ACKR2 下调或 CXCL14 诱导的 NOS1 减弱了 EMT 和迁移能力。CXCL14/ACKR2 的表达与基因表达数据集中的 EMT 和生存相关。
总的来说,这些发现表明成纤维细胞 CXCL14/ACKR2 途径是 EMT、肿瘤细胞侵袭和转移的一种临床相关刺激物。该研究还确定了 ACKR2 是 CXCL14 功能的新型介质,从而定义了具有药物靶潜力的途径。